NOMOCAN PHARMACEUTICALS LLC — Department of Health and Human Services SBIR Phase I: PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENT
NOMOCAN PHARMACEUTICALS LLC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $499,166. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
Nomocan Pharmaceuticals LLC received nearly $500,000 from the National Institutes of Health to develop new treatments or prevention methods for childhood cancers and rare cancers. This SBIR Phase I award supports early-stage research into therapeutic technologies.
- Amount
- $499,166
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- NY
- Period
- 2025-09-15 → 2027-09-14
Technology domains
Description
PHASE I - DEVELOPMENT OF THERAPEUTIC OR PREVENTATIVE TECHNOLOGIES FOR TREATMENT OR PREVENTION OF PEDIATRIC CANCERS AND/OR RARE CANCERS SBIR CONTRACTRIPTION.